Doxazosin
Product Images NDC 50090-2434

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 50090-2434). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Doxazosin-structure.jpg (Doxazosin Structure)

Chemical structure of Doxazosin, showing its molecular arrangement including aromatic rings, piperazine, and methoxy groups, as well as a methanesulfonic acid component.*

FDA Label Image

Figure1.jpg (Figure1)

This image contains two line graphs depicting clinical study results for Doxazosin versus placebo. The left graph shows mean change in total symptom score from baseline over 14 weeks, with Doxazosin demonstrating a greater reduction than placebo. The right graph shows mean increase in maximum urinary flow rate (mL/sec) from baseline over 14 weeks, with Doxazosin resulting in a higher increase compared to placebo. Statistical significance markers are included.*

FDA Label Image

Label Image (Lbl500902434)

Doxazosin 4 mg tablet bottle label from A-S Medication Solutions. The label includes product and lot numbers, storage temperature instructions (68-77°F), and states each tablet contains doxazosin mesylate equivalent to 4 mg doxazosin. The package contains 100 tablets. The label also indicates the package is distributed by A-S Medication Solutions, Libertyville, IL, with a note for prescription use only and directions to see the package insert.*

FDA Label Image

Table3.jpg (Table3)

A summary table of effectiveness data from placebo-controlled trials for Doxazosin, showing symptom score and maximum flow rate mean baseline values and changes across three studies with placebo and Doxazosin doses. Accompanying bar graph illustrates maximum flow rate increase and symptom score decrease for placebo and Doxazosin 4 mg and 8 mg doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.